Armata Pharmaceuticals announced that the U.S. FDA granted Breakthrough Therapy designation to AP-SA02 for the adjunct treatment of complicated bacteremia caused by methicillin-sensitive or methicillin-resistant Staphylococcus aureus. This designation, driven by Phase 2 data showing superior clinical cure rates compared to placebo plus best available antibiotic therapy, aims to expedite review and development. The company plans to initiate a Phase 3 superiority study in the second half of 2026. Armata Pharmaceuticals is a late-stage biotechnology company developing bacteriophage therapeutics for antibiotic-resistant bacterial infections.

Armata Pharmaceuticals reported a net income of $74.1 million for Q2 2026, driven by a $91.0 million non-cash gain from the change in fair value of its Convertible Loan. The company recognized $2.5 million in grant revenue and incurred $12.8 million in operating expenses. Cash balances rose to $24.0 million following a $25.0 million term loan, $2.4 million in ATM proceeds, and $1.2 million from option exercises. Clinically, Armata submitted its Phase 3 protocol for AP-SA02 to the FDA, received Fast Track designation, and secured an Agreed Initial Pediatric Study Plan. The company also announced the promotion of David House to Chief Financial Officer and the appointment of Daniel B. Gilmer to its Board of Directors. Armata Pharmaceuticals is a late clinical-stage biotechnology company focused on developing bacteriophage therapeutics for antibiotic-resistant bacterial infections.

Armata Pharmaceuticals announced clinical and regulatory progress for its AP-SA02 multi-phage product candidate, including the submission of a Phase 3 superiority study protocol and responses to FDA comments. The company completed four engineering runs at its Los Angeles manufacturing facility and plans to initiate the Phase 3 study in the second half of 2026. Additionally, Armata received a $2.5 million continuation award from the U.S. Department of Defense, bringing total funding under this award to $28.7 million. David House was promoted to Chief Financial Officer. Armata Pharmaceuticals is a biotechnology company developing bacteriophage therapeutics for antibiotic-resistant infections.

Armata Pharmaceuticals, Inc. promoted David House to Chief Financial Officer, effective July 17, 2026. Mr. House, who previously served as Senior Vice President, Finance and principal financial officer since August 2024, will receive an annual base salary of $371,315 and a target annual bonus of 50% of his base salary. The company also amended the definition of "change in control" in Chief Business Officer Pierre Kyme's employment agreement to align with Mr. House's agreement. Armata Pharmaceuticals, Inc. is a biotechnology company developing therapies for neurological diseases.

Armata Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has agreed to an Agreed Initial Pediatric Study Plan (Agreed iPSP) for the evaluation of AP-SA02 for treating complicated Staphylococcus aureus bacteremia (SAB) in pediatric patients. Armata Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutic solutions for infectious diseases.